Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
Dear Doctor Letter (Rote-Hand-Brief) on Esmya® 5 mg tablets (ulipristal acetate): restrictions of use, warnings regarding serious liver injury as well as recommendations for monitoring liver function
2018.02.19
Active substance: Ulipristal acetate
After reports of serious liver damage, including acute liver failure, in patients treated with Esmya® temporary measures have been taken.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN